z-logo
Premium
Multienzyme‐Mimic Ultrafine Alloyed Nanoparticles in Metal Organic Frameworks for Enhanced Chemodynamic Therapy
Author(s) -
Yang Peipei,
Tao Jia,
Chen Fengfeng,
Chen Yuying,
He Jiaqi,
Shen Kui,
Zhao Peng,
Li Yingwei
Publication year - 2021
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.202005865
Subject(s) - bimetallic strip , biocompatibility , nanoparticle , biosafety , cancer therapy , catalysis , materials science , nanotechnology , reactive oxygen species , glutathione , glutathione peroxidase , cancer treatment , in vivo , superoxide dismutase , chemistry , combinatorial chemistry , biophysics , antioxidant , enzyme , cancer , biochemistry , metallurgy , medicine , pathology , biology , microbiology and biotechnology
Nanozyme‐based chemodynamic therapy (CDT) has emerged as an effective cancer treatment because of its low side effects and without the requirement of exogenous energy. The therapeutic effect of CDT highlights the pivotal importance of active sites, H 2 O 2 supplement and the glutathione (GSH) depletion of a nanozyme. The construction of a single kind of catalyst with multiple functions for the enhanced CDT is still a big challenge. In this work, seven types of bimetallic nanoparticles are synthesized using a metal–organic framework (MOF) as a stable host instead of a Fenton or Fenton‐like ions supplier. Among them, Cu‐Pd@MIL‐101 with an alloy loading of 9.5 wt% modified by PEG (9.5% CPMP) is found to exhibit the highest peroxidase (POD) like activity combined with a superoxide dismutase (SOD) mimic activity and the function of GSH depletion. The in vivo results suggest that the stable and ultrafine nanoparticles possess favorable CDT effect for tumor and good biosafety as well as biocompatibility. This work has provided a credible strategy to construct nanozymes with an excellent activity and may pave a new way for the design of enhanced tumor CDT treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here